MOYOM Reaches Milestones in European Regenerative Aesthetics with APHRANEL® Certification and Collaboration
MOYOM, the innovative biotechnology enterprise known for its pioneering work on APHRANEL®, has recently announced two transformative achievements in its operations within Europe. These milestones, which include receiving the European Medical Device Regulation (EU MDR) certification and forming a strategic partnership with Expert2Expert (E2E) led by renowned aesthetic surgeon, Dr. Patrick Trévidic, underscore a new chapter in MOYOM’s ongoing commitment to advancing the field of regenerative aesthetics.
On July 7th, 2026, APHRANEL® successfully secured its EU MDR certification, awarded by BSI UK, an esteemed notified body within the industry. This certification is not merely a regulatory hurdle; it signifies the product's adherence to superior quality, safety, and clinical efficacy standards established by European regulations. The approval not only grants access to the European market for APHRANEL® but also positively impacts MOYOM’s international growth trajectory.
MOYOM's founder and CEO, Guangming Lin, emphasized the importance of earning the trust of physicians in tandem with regulatory approval. "Achieving market access marks just the initial step; the real challenge lies in fostering the confidence of healthcare professionals in our innovative products."
Following this regulatory success, MOYOM announced its collaboration with Expert2Expert (E2E), a notable independent scientific entity with over two decades of experience in the aesthetic medical field. The collaboration aims to establish a robust foundation for regenerative aesthetics across Europe, propelled by comprehensive anatomical studies, advanced cadaver research, and clinical evidence generation.
Dr. Patrick Trévidic will direct this initiative. Renowned for his extensive background in aesthetic surgery, scientific research, and education grounded in anatomy, Dr. Trévidic’s involvement signifies a strategic enhancement in the scientific integrity of regenerative aesthetic practices. His portfolio includes more than 75 peer-reviewed publications and globally acknowledged textbooks that underline his commitments to advancing medical knowledge and practices.
This partnership represents a convergence of MOYOM's advanced calcium hydroxyapatite technology and E2E's scientific acumen, ultimately constructing an evidence-centered and educational framework aimed at advancing clinical practices. Aside from anatomical research, their joint efforts will focus on creating ongoing education for physicians, facilitating European clinical research, and fostering international scientific collaboration.
Patrice Delobel, PhD, who serves as the European Medical and Marketing Director at MOYOM, stated, "My aspirations in joining MOYOM transcended merely overseeing the European launch of APHRANEL®. I yearned to forge a scientific platform that physicians can depend on for years ahead. This collaboration with Expert2Expert, led by Dr. Trévidic, signifies one of the most pivotal steps toward that vision."
Dr. Patrick Trévidic, aligned with this ambitious vision, reiterated, "Scientific advancement is not the achievement of a single entity. It is birthed through collaboration, curiosity, and the relentless quest for stronger evidence. I am excited that Expert2Expert can partner with MOYOM on this expedition to realize the scientific foundations essential for the future of regenerative aesthetics in Europe."
These two critical milestones pave the groundwork for MOYOM’s dedication to scientific progress, encapsulated in the notion of 'Care Lifetime Value.' This philosophy emphasizes a patient-centric approach wherein:
MOYOM remains steadfast in its pursuit of scientific inquiry, medical education, and collaborative efforts, continuously enhancing the landscape of regenerative aesthetics. From laboratory innovations to clinical applications, the overarching goal is clear: building trust through evidence, which in turn stimulates adoption and ultimately elevates the quality of patient care across Europe.
On July 7th, 2026, APHRANEL® successfully secured its EU MDR certification, awarded by BSI UK, an esteemed notified body within the industry. This certification is not merely a regulatory hurdle; it signifies the product's adherence to superior quality, safety, and clinical efficacy standards established by European regulations. The approval not only grants access to the European market for APHRANEL® but also positively impacts MOYOM’s international growth trajectory.
MOYOM's founder and CEO, Guangming Lin, emphasized the importance of earning the trust of physicians in tandem with regulatory approval. "Achieving market access marks just the initial step; the real challenge lies in fostering the confidence of healthcare professionals in our innovative products."
Following this regulatory success, MOYOM announced its collaboration with Expert2Expert (E2E), a notable independent scientific entity with over two decades of experience in the aesthetic medical field. The collaboration aims to establish a robust foundation for regenerative aesthetics across Europe, propelled by comprehensive anatomical studies, advanced cadaver research, and clinical evidence generation.
Dr. Patrick Trévidic will direct this initiative. Renowned for his extensive background in aesthetic surgery, scientific research, and education grounded in anatomy, Dr. Trévidic’s involvement signifies a strategic enhancement in the scientific integrity of regenerative aesthetic practices. His portfolio includes more than 75 peer-reviewed publications and globally acknowledged textbooks that underline his commitments to advancing medical knowledge and practices.
This partnership represents a convergence of MOYOM's advanced calcium hydroxyapatite technology and E2E's scientific acumen, ultimately constructing an evidence-centered and educational framework aimed at advancing clinical practices. Aside from anatomical research, their joint efforts will focus on creating ongoing education for physicians, facilitating European clinical research, and fostering international scientific collaboration.
Patrice Delobel, PhD, who serves as the European Medical and Marketing Director at MOYOM, stated, "My aspirations in joining MOYOM transcended merely overseeing the European launch of APHRANEL®. I yearned to forge a scientific platform that physicians can depend on for years ahead. This collaboration with Expert2Expert, led by Dr. Trévidic, signifies one of the most pivotal steps toward that vision."
Dr. Patrick Trévidic, aligned with this ambitious vision, reiterated, "Scientific advancement is not the achievement of a single entity. It is birthed through collaboration, curiosity, and the relentless quest for stronger evidence. I am excited that Expert2Expert can partner with MOYOM on this expedition to realize the scientific foundations essential for the future of regenerative aesthetics in Europe."
These two critical milestones pave the groundwork for MOYOM’s dedication to scientific progress, encapsulated in the notion of 'Care Lifetime Value.' This philosophy emphasizes a patient-centric approach wherein:
- - Care entails unwavering support through disciplined science, secure practices, and enlightened education.
- - Lifetime symbolizes the commitment to instilling lasting trust among physicians via continuous learning and evidence-sharing.
- - Value denotes the generation of substantive impacts across the healthcare ecosystem, benefiting patients, physicians, and scientific collaborators alike.
MOYOM remains steadfast in its pursuit of scientific inquiry, medical education, and collaborative efforts, continuously enhancing the landscape of regenerative aesthetics. From laboratory innovations to clinical applications, the overarching goal is clear: building trust through evidence, which in turn stimulates adoption and ultimately elevates the quality of patient care across Europe.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.